For key US eVTOL players Joby Aviation and Archer Aviation, the Paris Air Show comes at a critical moment.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
NASA is looking to decrease its dependency on key contractor SpaceX, but Jeff Bezos’s Blue Origin is going nowhere at exactly the wrong time.
Elon Musk is again sleeping at Tesla’s offices again, but that may not be enough to restart the top US EV-maker’s engine.
The Switch 2 sold 3.5 million units in its first four days, and Nintendo’s targeting 15 million units for this fiscal year.
In an interview with the Financial Times, Starbucks CEO Brian Niccol said the company is exploring a partial sale of its China business.
Could GLP-1 weight loss drugs like Ozempic and changing economic winds really take a bite out of the almighty Big Mac?
Like the rest of its pre-streaming Hollywood peers, Warner Bros. Discovery finds itself trapped between two eras.
Scale for scale’s sake appears to have become passé, with conglomerates jockeying for market share with a more focused brand identity.
Cyber-criminals often see healthcare firms’ shoddy protection as a “pot of gold.”
An increasing share of NBA endorsement deals has been spread among shoe firms fighting for a piece of Nike’s market share.
As China tightens its grip on rare earths exports, one of its most crucial bargaining chips, the global supply chain is showing cracks.
Snacks now make up around half of the historic soup company’s sales, up from less than a third a decade ago.
At the heart of the biotech deal is a relatively new drug technology called PD-1/VEGF bispecific antibodies.
Brands that cater to the uber wealthy saw a dip in sales for the first quarter of 2025, continuing a slowdown that started last year.
The agreement comes as The New York Times continues to sue OpenAI and Microsoft for alleged copyright infringement.
2025 is projected to be an unusually terrible year for the US travel industry — and only the US travel industry.